TY - JOUR
T1 - A multimodal approach for clinical diagnosis and treatment of Primary Progressive Aphasia (MAINSTREAM): a study protocol
AU - Cotelli, Maria
AU - Baglio, Francesca
AU - Manenti, Rosa
AU - Blasi, Valeria
AU - Galimberti, Daniela
AU - Gobbi, Elena
AU - Pagnoni, Ilaria
AU - Rossetto, Federica
AU - Rotondo, Emanuela
AU - Esposito, Valentina
AU - De Icco, Roberto
AU - Giudice, Carla
AU - Tassorelli, Cristina
AU - Catricalà, Eleonora
AU - Perini, Giulia
AU - Alaimo, Cristina
AU - Campana, Elena
AU - Benussi, Luisa
AU - Ghidoni, Roberta
AU - Binetti, Giuliano
AU - Carandini, Tiziana
AU - Cappa, Stefano Francesco
PY - 2023
Y1 - 2023
N2 - Primary Progressive Aphasia (PPA) is a syndrome due to different neurodegenerative disorders selectively disrupting language functions. PPA specialist care is underdeveloped. There are very few specialists (neurologists, psychiatrists, neuropsychologists, and speech therapists) and few hospital- or community-based services dedicated to the diagnosis and continuing care of people with PPA. Currently, healthcare systems struggle to provide adequate coverage of care that is too often fragmented, uncoordinated, and unresponsive to the needs of people with PPA and their families. Recently, attention has been gained by non-invasive brain stimulation techniques that allow a personalized treatment approach, such as transcranial Direct Current Stimulation (tDCS). The MAINSTREAM trial looks forward to introducing and evaluating therapeutic innovations such as tDCS coupled with language therapy in rehabilitation settings. A Multimodal Approach for Clinical Diagnosis and Treatment of Primary Progressive Aphasia, MAINSTREAM (ID: 3430931) was registered in the clinicaltrials.gov database (identifier: NCT05730023) on 15 February 2023.
AB - Primary Progressive Aphasia (PPA) is a syndrome due to different neurodegenerative disorders selectively disrupting language functions. PPA specialist care is underdeveloped. There are very few specialists (neurologists, psychiatrists, neuropsychologists, and speech therapists) and few hospital- or community-based services dedicated to the diagnosis and continuing care of people with PPA. Currently, healthcare systems struggle to provide adequate coverage of care that is too often fragmented, uncoordinated, and unresponsive to the needs of people with PPA and their families. Recently, attention has been gained by non-invasive brain stimulation techniques that allow a personalized treatment approach, such as transcranial Direct Current Stimulation (tDCS). The MAINSTREAM trial looks forward to introducing and evaluating therapeutic innovations such as tDCS coupled with language therapy in rehabilitation settings. A Multimodal Approach for Clinical Diagnosis and Treatment of Primary Progressive Aphasia, MAINSTREAM (ID: 3430931) was registered in the clinicaltrials.gov database (identifier: NCT05730023) on 15 February 2023.
KW - imaging biomarkers
KW - language training
KW - molecular biomarkers
KW - primary progressive aphasia
KW - transcranial Direct Current Stimulation
KW - imaging biomarkers
KW - language training
KW - molecular biomarkers
KW - primary progressive aphasia
KW - transcranial Direct Current Stimulation
UR - http://hdl.handle.net/10807/270350
U2 - 10.3390/brainsci13071060
DO - 10.3390/brainsci13071060
M3 - Article
SN - 2076-3425
VL - 13
SP - 1
EP - 16
JO - Brain Sciences
JF - Brain Sciences
ER -